



Clinical Testing Framework: Guide to collaborate legally and ethically


Interreg 
North-West Europe
IT4ANXIETY
European Regional Development Fund



Table of Contents

Overview	3
What does this document do?	3
How to use this document	3
What is clinical testing?	4
Clinical Testing Models: What are the types of clinical trials?	5
Clinical trial phases	6
Do I need to run a clinical trial?	7
Other forms of clinical testing	8
Ethics	10
Study protocols	12
Using a study protocol	13
Critical steps of a study protocol	14
IT4Anxiety Startup Testing Designs	17
Relevant Laws, Regulations, and Guidelines – UK example	21
Implications of Non-Compliance and Legal Risks	22
Examples of successful legal and ethical collaboration	23
Document Summary	25
References	26

Overview 2023



Clinical testing framework



What does this document do?

This document is intended to provide an overview of the clinical and testing validation process. It does not offer specific regional examples; therefore, further guidance should be sought regarding your region's legal frameworks.

How to use this document

This clinical testing framework document is a guide produced as part of the IT4Anxiety project. It is intended that this guide provides a high-level overview of what a clinical trial is, how they are implemented and what other forms of testing can be used in place of clinical trials. This is discussed further in sections such as 'Do I need a clinical trial'. In addition, a framework has been produced in Figure 2, which provides a short overview of deciding whether a clinical trial is suitable for your product. Similarly, Figure 3 provides a guide on which types of evidence should be prioritised during reporting and building product evidence base.

What is clinical testing?

The evolution of the modern clinical trial dates back at least to the eighteenth century. The concept of randomisation was introduced by Fisher and applied in agricultural research in 1926 [1, 2].

The first clinical trial that used a form of random assignment of participants to study groups was reported in 1931 [2]. In the past several decades, the randomised clinical trial has emerged as the preferred method for evaluating medical interventions [1, 2].

From the scientific perspective, experiments, as per Hasson 2014, are when an object of study is subjected to various interventions to obtain a predictable outcome to some extent [1]. Similarly, should the experiment

(1) aim to achieve a desired goal of human action and

(2) aim to deploy such actions within a non-experimental setting to achieve the same outcome, then the above may also be thought of as action-guiding experiments [1].

Finally, the alternative is an epistemic experiment that aims to derive information about the workings of our world [1, 2].

Clinical trials, compared to observational studies, are considered by many to be the gold standard method for the evaluation of healthcare interventions [1, 3]. Clinical trials are specifically developed to establish the efficacy of treatment effects, which take precedence over all other types of studies so far as treatment effects are concerned [1]. Clinical trials, however, are not the only form of experiments that advances human health knowledge. Studies such as laboratory experiments and clinical case reports are equally valid but take different precedence regarding the evidence offered [1].

A clinical trial is a research project that compares two or more treatments in patients with a particular condition or at risk of a need to help generate high-quality evidence about which is the more effective treatment or preventative strategy [1, 2, 3]. The therapy investigated in a clinical trial can be a medicinal product, procedure, device, or therapeutic intervention [3]. Clinical trials are an essential part of the process of evidence-based practice and can help guide treatment decisions for healthcare professionals and patients. In addition, clinical trials are an integral part of the pathway by which new medicinal products can obtain a licence from MHRA and become available as a new treatment in patients [3].

Clinical Testing Models: What are the types of clinical trials?

A clinical trial is a prospective study comparing the effects and value of intervention (s) against a control in human beings.

Study participants must be followed forward in time. With the increasing availability of electronic health records, this research has become more feasible and may involve thousands of individuals. A clinical trial must employ one or more intervention techniques. These may be single or combinations of diagnostic, preventive, or therapeutic drugs, biologics, devices, regimens, procedures, or

educational approaches. Using our definition, a trial contains a control group against which the intervention group is compared. Follow-up of people over some time without active intervention may measure the natural history of a disease process, but it does not constitute a clinical trial. Unlike animal studies, the investigator cannot dictate what an individual should do in clinical trials. He can only strongly encourage

participants to avoid certain medications or procedures which might interfere with the prosecution. The ideal clinical trial is randomised and double-blind. Deviation from this standard has potential drawbacks. Poorly designed, conducted, analysed, and reported trials foster confusion and even erroneous interpretation of results.




Figure 1: Types of studies for various clinical trial phases. The X-axis denotes the trial phase, while the Y-axis indicates a sample of the types of clinical tests that may be carried out [2].

Clinical trial phases:



Phase 1

This is the first stage of clinical trials and typically involves a small number of healthy volunteers to test the safety and dosing of a new treatment or intervention [3].



Phase 2

These trials involve a larger group of patients with the target disease or condition to test the effectiveness of the new treatment, as well as to continue monitoring safety [3].



Phase 3

These are large-scale trials that involve thousands of patients and are designed to provide definitive evidence of the safety and effectiveness of the new treatment [3].



Phase 4

Also known as post-marketing surveillance, these trials are conducted after a new treatment has been approved and made available to the public. The purpose of these trials is to continue monitoring the safety and effectiveness of the treatment in a larger population over a more extended period [3].

Do I need to run a clinical trial?

The need for clinical testing in developing a product or intervention depends on various factors, including the product's nature and the intended market's regulatory requirements.

For drugs, medical devices, and biological products, clinical testing is typically required by regulatory authorities to assess safety and efficacy before approval for sale. For example, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both emphasise the importance of clinical trials in the drug development process and require them for most new drugs and biologics intended for human use [4, 5].

However, clinical testing may not be mandatory or optional for non-medical products or interventions, such as consumer products or digital health tools, depending on the intended use and potential risks involved. While regulatory authorities may not require clinical trials in such cases, conducting clinical studies can still provide valuable data on safety and efficacy, informing decision-making and providing evidence to stakeholders.

To ensure compliance with the appropriate testing and approval requirements, it is essential to consult regulatory experts and legal counsel familiar with the specific product or intervention and the relevant regulatory landscape. This will help navigate the regulatory process and address additional considerations specific to your product or intervention.

In summary, the necessity of clinical testing varies depending on the nature of the product or intervention and the regulatory requirements of the target market. For example, regulatory authorities such as the FDA and the EMA require clinical trials for most new drugs and biologics. In contrast, clinical testing may be optional for non-medical products or interventions. Therefore, consulting regulatory and legal professionals is crucial to understanding and meeting your product or intervention's testing and approval requirements.



Other forms of clinical testing?

Health researchers play a crucial role in addressing a diverse range of clinical research questions, ultimately leading to the development of interventions that have the potential to save lives. The effectiveness of these interventions is established through rigorous scientific investigation.


When conducting clinical research, researchers categorise studies based on whether they assign a specific exposure or intervention to a cohort of participants. For instance, in a trial designed to test the effectiveness of a new medication, investigators assign the exposure, which in this case is the medication being studied.

It is important to note that not all study types are suitable for addressing every clinical question. The choice of study design depends on the nature of the research question and the feasibility of implementing a particular strategy. For instance, if the research question revolves around investigating the impact of maternal smoking on foetal development, a randomised controlled trial (RCT) would not be appropriate or ethical. RCTs randomly assign participants to different intervention groups, making it impractical and unethical to give pregnant women to smoke or not smoke as part of a controlled trial.

Instead, observational study designs, such as cohort studies or case-control studies, would be more suitable for investigating the impact of maternal smoking on foetal development. These designs allow researchers to observe and analyse the associations between exposure (in this case, maternal smoking) and outcomes (foetal development) without manipulating or assigning exposures to participants.

By carefully selecting the appropriate study design, researchers can ensure that their investigations align with ethical considerations, address specific research questions effectively, and provide reliable evidence for guiding clinical practice and interventions.

Health researchers employ various study designs to answer different clinical research questions. While randomised controlled trials are valuable for assessing interventions, they may not be appropriate or ethical for investigating specific exposures. Nevertheless, researchers can generate valuable evidence to improve health outcomes and save lives by choosing the most appropriate study design for each research question.



Study design flowchart






Figure 2: Study design flowchart [6]

Ethics

Ethical considerations are paramount in clinical testing to safeguard study participants' rights, welfare, and well-being. The ethics process involves steps to ensure the study adheres to ethical principles and regulations.




Firstly, obtaining ethical approval from the appropriate institutional review board (IRB) or ethics committee is a fundamental requirement. The IRB or ethics committee carefully reviews the study protocol, informed consent procedures, and other relevant documentation to assess the research's ethical implications and potential risks and benefits [7].

Informed consent is a critical aspect of the ethics process. Participants must be provided comprehensive information about the study, including its purpose, procedures, potential risks, benefits, and alternatives. In addition, they should be able to ask questions and make an informed decision about their participation. Written informed consent is typically obtained from participants or their legally authorised representatives [8].

Respect for participant autonomy and privacy is essential. Confidentiality measures should be implemented to protect participants' personal information, ensuring their privacy throughout the study. Data anonymisation or de-identification techniques may be employed to safeguard participant identities further [9].

In addition to individual participant consent, the principle of justice necessitates careful consideration of equitable participant selection. Therefore, the selection criteria should be fair and justifiable, avoiding discrimination or biases in participant recruitment and enrolment [10].



The principle of beneficence requires maximising potential benefits and minimising risks to participants. Study interventions should be designed to provide potential benefits to participants while minimising any foreseeable risks. Adequate monitoring of participant safety and well-being throughout the study is crucial, and steps should be taken to address and mitigate any adverse events that may occur [10].

Researchers are responsible for ensuring that conflicts of interest are identified and managed appropriately. Therefore, transparency in disclosing financial, professional, or other potential conflicts is essential to maintain the research process's integrity and the participants' trust [11].

Ongoing ethical considerations extend beyond the commencement of the study. For example, regular trial monitoring, including data and safety reviews, helps ensure participant safety and study integrity. In addition, ethical oversight continues throughout the study to assess the ongoing balance of risks and benefits, adherence to ethical guidelines, and any emerging ethical issues [12].

In summary, the ethics process in clinical testing involves obtaining ethical approval, obtaining informed consent, protecting participant privacy and confidentiality, ensuring equitable participant selection, maximising benefits while minimising risks, managing conflicts of interest, and maintaining ongoing ethical oversight. These processes collectively uphold the principles of autonomy, privacy, justice, beneficence, and integrity and contribute to the ethical conduct of clinical research.

Study protocols

The rigorous evaluation of health technologies through well-designed clinical trials is paramount in the rapidly evolving healthcare landscape.

Every successful clinical trial begins with a meticulously crafted study protocol, which serves as a written agreement between investigators, participants, and the scientific community. This chapter examines study protocols for clinical testing health technologies, elucidating their significance, contents, and evolving trends.

The role of a study protocol must be balanced. The protocol is a comprehensive document that outlines a clinical trial's background, objectives, design, and organisation [13]. While it is optional to include every minute detail in the protocol itself, a comprehensive manual of procedures is essential to ensure the consistency and reproducibility of the trial. In addition, the protocol not only assists in communication among trial personnel but also serves as a vital reference for researchers and clinicians who wish to replicate or validate the study findings.

In recent years, there has been a notable shift towards publishing study protocols in online journals, contributing to the transparency and accessibility of clinical research. The increased availability of protocols allows interested parties to gain insights into the rationale behind study design choices and to evaluate the integrity of trial conduct. Furthermore, as advocated by the International Committee of Medical Journal Editors [14], registering clinical trials in reputable registries has become a prerequisite for publication in many leading journals. Clinical trial registries, such as the WHO International Clinical Trials Registry Platform (ICTRP) [15] and ClinicalTrials.gov [16], provide an avenue for researchers to register their trials and make critical information available to the scientific community.

The benefits of trial registration are manifold. Firstly, it significantly reduces the risk of publication bias, ensuring that trial results are not left unpublished or unknown [17]. Moreover, it enables a comparison between the initially described study design and the subsequently published findings, allowing for an assessment of any modifications or deviations that may have occurred during the trial. Furthermore, trial registration empowers researchers to stay informed about ongoing studies in their respective areas of interest, preventing duplication of efforts and fostering collaboration [17].

Notably, regulatory bodies and funding agencies have also recognised the importance of trial registration. For example, the U.S. National Institutes of Health (NIH) requires trials of its funds to be registered [18], and the Food and Drug Administration (FDA) mandates registration for trials under its oversight [19]. These measures underscore the commitment to transparency, accountability, and the responsible conduct of clinical research.

In this chapter, we will delve into the key elements that comprise a well-designed study protocol, exploring the rationale and considerations behind each component. Additionally, we will examine the evolving landscape of clinical trial registration, highlighting the significance of registries such as ClinicalTrials.gov and the ICTRP. Finally, drawing on insights from registry data, we will shed light on the characteristics of registered trials and the prevailing trends in study design. As we embark on this comprehensive exploration of study protocols for clinical testing of health technologies, we encourage researchers, clinicians, and stakeholders to recognise the crucial role of protocols in advancing evidence-based healthcare and fostering scientific progress.

Using a study protocol

Implementing a study protocol is a crucial step in conducting clinical research. Once the protocol is finalised, it serves as a comprehensive guide that outlines the specific procedures and actions to be followed throughout the study. The implementation of a study protocol involves several vital aspects.

Firstly, the protocol is shared with the research team, including investigators, study coordinators, and other relevant personnel. Ensuring that all team members are familiar with the protocol and understand their roles and responsibilities is essential. Clear communication and regular meetings or training can facilitate effective implementation.

Next, the protocol's procedures are put into action. This includes participant recruitment and enrolment, intervention administration or exposure, data collection, and follow-up assessments. Adhering to the protocol's instructions and maintaining consistency in the execution of these procedures is crucial to ensure the reliability and validity of the study results.

The study team follows the protocol's guidelines for data management, including data collection tools, storage methods, and quality control measures. Data monitoring and auditing procedures may also be implemented to ensure data accuracy and integrity.

Throughout the study, adherence to ethical considerations outlined in the protocol is of utmost importance. Informed consent procedures should be followed meticulously, ensuring that participants fully understand the study's purpose, policies, risks, and benefits before participating.

Regular monitoring and oversight of the study's progress are typically conducted, as outlined in the protocol. This may involve scheduled meetings, participant data

review, protocol deviation assessment, and reporting adverse events or unexpected outcomes. The protocol may also outline the establishment of a data monitoring committee or an independent safety monitoring board for trials involving higher risks.

Flexibility and adaptability are also essential during implementation. While the protocol is a guiding document, unanticipated circumstances or unforeseen challenges may require protocol amendments or adaptations. In such cases, careful consideration and documentation of the rationale for changes should be done, ensuring that any modifications are consistent with ethical guidelines and are appropriately reviewed and approved by relevant authorities.

Close adherence to the protocol's guidelines, effective communication within the research team, and ongoing monitoring and quality assurance measures are vital throughout the implementation process. These efforts collectively ensure that the study is conducted in a standardised, rigorous, and ethical manner, leading to valid and reliable results.

Implementing a study protocol requires the collaborative efforts of the research team, adherence to ethical considerations, and careful execution of the outlined procedures. By following the protocol diligently, researchers can ensure the study's integrity, validity, and scientific rigour, ultimately contributing to advancing knowledge in clinical research.

Critical steps of a study protocol

Several key steps are detailed within a study protocol for clinical testing to ensure a well-designed and well-executed trial. The following are the main steps typically included in a study protocol:

Trial Management and Monitoring

Study characteristics, aims & objectives

Background and Rationale

The protocol provides a comprehensive overview of the background information and rationale for conducting the study. This section establishes the context and justifies the need for the research [20].

Objectives and Research Questions

Clear and specific objectives and research questions are outlined in the protocol. These serve as the guiding principles for the study, ensuring that the research goals are well-defined and measurable [20].

Study Design

The study design section describes the overall structure and approach of the trial. It includes details on the study type (e.g., randomized controlled trial, observational study), the selection of participants, and the allocation of interventions or exposures [20].

Recruitment & intervention

Participant Eligibility and Recruitment

The protocol specifies the criteria for participant eligibility, including age, gender, medical conditions, and other relevant factors. It outlines the recruitment strategies, such as recruitment sites, recruitment methods, and sample size calculations [20, 21].

Interventions or Exposures

This section outlines the specific interventions or exposure being tested in the trial. It includes detailed descriptions of the experimental and control interventions, dosages, administration procedures, and any modifications or adaptations [20].

Outcome Measures

The protocol defines the primary and secondary outcome measures used to assess the effectiveness and safety of the interventions. It provides clear definitions, methods of measurement, and the timing of assessments [20, 21].



Trial Management and Monitoring

Ethics, Data & Analysis

Data Collection and Management

This step details the data collection procedures, including the collection tools, data sources, and data management processes. It may also address data monitoring, quality control, and participant confidentiality [20, 21].

Statistical Analysis

The protocol outlines the statistical methods that will be used to analyse the collected data. This includes descriptions of the primary analysis, subgroup analyses, interim analyses, and any adjustments for multiple comparisons [20].

Ethical Considerations and Informed Consent

This section highlights the ethical principles and procedures to be followed throughout the trial. It addresses participant safety, informed consent processes, ethical approval, and potential risks and benefits of participation [20, 21].

Study management

Timeline and Milestones

The protocol includes a detailed timeline that outlines the planned duration of the trial, key milestones, and important events such as participant enrolment, intervention administration, follow-up assessments, and data analysis [20].

Dissemination of Results

This section addresses the plans for result dissemination, including publication in peer-reviewed journals, conference presentations, and any additional knowledge translation strategies [20].

Figure 3: Core components of a study protocol

By including these main steps within a study protocol, researchers can ensure that the trial is well-structured, ethical, and scientifically robust. The protocol provides a comprehensive roadmap for conducting the study, guiding the research team through each stage of the clinical testing process.

Clinical trial flowchart





Figure 4: Implementation of clinical trial flowchart

IT4Anxiety Startup Testing Designs

As part of the IT4Anxiety project, the participating startups submitted a comprehensive study protocol which served as a framework for evaluating the safety, delivery methods, accessibility, and effectiveness of their intervention in a test environment. Figures 5 to 10 below present an overview of the testing designs employed by six of the startups, AARDEX Group, Cerina, ELDOM, Healthy Mind, Sentimentics and TL Tech Ltd (Kindspace). Each overview contains the study title, study type, primary and secondary aims and information on the participants, measurements used, overall design and preliminary results. All testing was carried out as part of the IT4Anxiety project – note some of the studies are still running at the time of writing this document.



AARDEX GROUP

Study of adherence to treatment using a mobile application and a connected button (MEMS button)

Aims

- Assess the usability of AARDEX Group's solution, MEMS® Mobile, with patients undergoing medical treatment
- Evaluate the impact of the MEMS® Button and the MEMS® Mobile application on the level of anxiety
- Evaluate satisfaction & feasibility

Study type: Feasibility

Participants (n=42)

- Adults >18 yrs old
- Chronic illness & consume medication independently
- Own a Smartphone
- French speaking

Measurements

- Adherence via MEMS app
- Client satisfaction questionnaire-8
- System usability scale
- Hospital anxiety & depression scale

Design

- Community testing site
- Liege University
- 3-month duration
- Anxiety measured pre & post
- Satisfaction, usability & adherence measured post study

Results

- 19 participants preliminary results:
- 3months with the MEMS® digital solution, treatment-related anxiety significantly decreased (43.6 versus 34.9, p=0.031)

Figure 5: AARDEX Group IT4Anxiety testing overview



CERINA

Cognitive Behavioral Therapy based mobile application for managing General Anxiety Disorder (GAD) symptoms: A Pilot Randomised Controlled Trial

Aims

- Assess preliminary effect of Cerina app (intervention) on anxiety & worrying symptoms compared to student well-being services (control)
- Assess adherence rates to using app
- Examine recruitment procedures and participants' willingness to be randomized to a treatment group or waiting list control group
- Obtain presentations on usability of the apps Interface Design.

Study type: Pilot RCT

Participants (n=90)

- Adults >18 yrs old
- Student cohort from Ulster Uni
- N=45 in two groups: 1) treatment; and 2) waitlist
- Showing only mild to moderate anxiety symptoms
- Fluent in English
- Access to smart phone or tablet

Measurements

- General Anxiety Disorder Questionnaire (GAD-7)
- Penn State Worry Questionnaire (PSWQ)
- Patient Health Questionnaire (PHQ9)
- Work Social Adjustment Scale (WSAS)
- System usability scale (SUS)
- Semi-structured interviews

Design

- Students split into two groups (Cerina & Uni Well-being services)
- GAD-7, PSWQ-PW, PHQ9 & WSAS measured at baseline (T0), week-3 (T1) and week-6 (T2)
- SUS measured at T-1 and T-2
- Semi-structured interviews at T-2

Results

- Ongoing



Figure 6: Cerina IT4Anxiety testing overview

ELDOM

How can photoluminescence influence the anxiety level of patients

Aims

- To test the usability of photoluminescence as a substitute for light left on at night
- Assess sleep quality in participants before and after intervention via questionnaires
- Report observations given by caregivers concerning sleep quality of patients

Study type: Feasibility

Participants (n=17)

- Vulnerable older adults >60 yrs old.
- Saint-Martin Neuro Psychiatric Hospital & NHS Scotland Western Isles Care Home

Measurements

- System usability scale (SUS)
- Hospital Anxiety and Depression Scale (HADS)

Design

- Luminescent signs were implemented in participant rooms for 30 days
- HADS to be completed pre/ post experiment, and 5 days after signs were removed from rooms

Results

- 8 residents - reduced anxiety
- 3 residents – no change
- 3 residents – anxiety worse



Figure 7: ELDOM IT4Anxiety testing overview

HEALTHY MIND VR

The ability of subversive VR experiences combining neuroscience, hypnotherapy and psychological principles to reduce feelings of anxiety in patients.

Aims

- Examine the effect of 6 x immersive VR with hypnotic audio on level of anxiety, wellbeing and emotions
- Examine the effect of a single immersive VR with hypnotic audio wellbeing and emotions
- Standardize and systematize practices in order to monitor their effectiveness, while also making them more accessible (easy to implement) to caregivers and their patients.

Study type: Feasibility

Participants (n=13)

- Inclusion - hospitalised at CNP St Martin, over 18 yrs old
- Exclusion – history of epilepsy, panic disorder with claustrophobia, consumption of alcohol/ illicit substances

Measurements

- SCL-90
- Emotional Reactivity Scale (ERS)
- Emotions basic questionnaire
- Cyber sickness survey

Design

- Study A: The subject will participate in the study for 6 weeks.
- Study B: The subject will participate in a session of approximately one hour

Results

- Testing completed
- Evaluation of the experience at the present moment suggests VR + hypnotic audio has positive effects on wellbeing directly after VR session
- SCL-90R, the ERS and the Basic Emotions questionnaire – not significant



Figure 8: Healthy Mind IT4Anxiety testing overview

KINDSPACE

How does using the Kindspace voice application change feelings of worry in individuals?

Aims

- Determine if there is a reduction in worry symptoms after regularly using a voice application for Amazon Alexa (Kindspace)
- Obtain participants' views on the quality and usability of the User Interface Design.
- Examine adherence rates in the use of the Kindspace voice app.

Study type: Useability

Participants (n=33)

- Adults >18 yrs old, male & female.
- Online participants Netherlands and UK

Measurements

- Penn State Worry Questionnaire - Past Week (PSWQ-PW)
- System Usability Scale
- Adherence rates

Design

- 6-week study duration
- 3 measurement time points: T1 (baseline), T2 (3-weeks), T3 (6-weeks)
- PSWQ-PW measured at all 3 time points
- System Usability Scale measured at T2 & T3, only

Results

- PSWQ-PW scores decreased significantly between all 3 time points (p<0.05)
- System usability was deemed high (>70%) and significantly improved from T1 to T2 (p<0.05)



Figure 9: Kindspace IT4Anxiety testing overview

SENTIMENTICS Aims

Assessing the performance of a multi-modal algorithm developed in recognition of stress in an individual.

- The current study aims at assessing the performance of a multi-modal algorithm developed in recognition of stress in an individual during a stress inducing experiment

Study type: Feasibility

Participants (n=19)

- Healthy adults >18 yrs old
- Students of the Vrije Universiteit Amsterdam

Measurements

- State and Trait Anxiety Inventory-Alternate Form(STAI-A)
- Subjective Units of Distress Scale(SUDS)
- VU-AMS - an ambulatory monitoring system for the measurement of heart rate variability and skin conductance

Design

- 90 min cubicle lab test.
- Participants were not informed of the true nature of the experimental design until afterwards
- The VU-AMS was applied to each subject before the Trier Social Stress Test (TSST) was administered to induce stress
- SUDS and STAI-A were assessed pre & post TSST

Results

- SUDS scores were significantly higher during the TSST compared to baseline and post-test recovery period ($p < .05$)
- Work still ongoing for prediction of continuous ratings of stress through the algorithm

Figure 10: Sentimentics IT4Anxiety testing overview



Relevant Laws, Regulations and Guidelines

UK example

The scope of this guide does not allow for an analysis of relevant regulations for each of the partner countries, instead laws, regulations and guidelines for the United Kingdom (UK) are presented as an exemplar. In the UK clinical testing is subject to a range of laws, regulations, and guidelines that ensure the safety, efficacy, and ethical conduct of medical research. Here's an overview of the relevant legal framework, along with the implications of non-compliance and potential legal risks:

Relevant Laws, Regulations, and Guidelines:



1. Medicines and Healthcare products Regulatory Agency (MHRA):

The MHRA is the UK's regulatory authority for medicines, medical devices, and clinical trials. It oversees the implementation of regulations that ensure the quality, safety, and efficacy of medical products.

2. Clinical Trials Regulation:

Clinical trials in the UK are governed by the Clinical Trials Regulation, which incorporates the principles of the EU Clinical Trials Directive (2001/20/EC) and the EU Clinical Trials Regulation (536/2014). The regulation outlines requirements for obtaining ethics committee approval, informed consent, and reporting of trial results.



3. Medicines for Human Use (Clinical Trials) Regulations:

These regulations provide detailed guidance on the conduct of clinical trials, including the role of ethics committees, informed consent procedures, and the reporting of adverse events.



4. Data Protection Laws:

The UK is subject to the General Data Protection Regulation (GDPR) and the Data Protection Act 2018. These laws govern the collection, processing, and protection of personal data, including health-related data collected during clinical trials.



5. Human Tissue Act 2004:

This Act regulates the removal, storage, use, and disposal of human tissue for research purposes. It includes provisions for obtaining proper consent and conducting research involving human tissue ethically and legally.



6. Good Clinical Practice (GCP) Guidelines:

GCP guidelines provide a framework for conducting clinical trials ethically and with scientific rigor. They cover aspects such as trial design, subject protection, data integrity, and trial reporting.



7. Research Ethics Committees (RECs):

These committees review and approve the ethical aspects of clinical trials. They ensure that the rights, safety, and well-being of trial participants are protected.



Implications of Non-Compliance and Legal Risks

Non-compliance with the laws, regulations, and guidelines governing clinical testing in the UK can have significant legal and ethical consequences:



1. Regulatory Sanctions

Failure to obtain necessary approvals from regulatory bodies, such as the MHRA, can result in penalties, fines, or even criminal prosecution. Trials conducted without proper authorization may be deemed invalid.



2. Civil and Criminal Liability

Non-compliance with data protection laws or ethical requirements can lead to civil lawsuits or criminal charges. Mishandling of personal data or inadequate informed consent procedures can result in legal action.



3. Invalid Trial Results

Trials conducted without adhering to GCP guidelines may produce unreliable or invalid results, undermining the scientific integrity of the research.



4. Reputational Damage

Non-compliance can lead to negative publicity, damaging the reputation of the researchers, institutions, and sponsors involved in the clinical trial.



5. Ethical Concerns

Non-compliance can raise ethical concerns related to participant safety, rights, and autonomy. It may erode public trust in clinical research.



6. Hindrance to Medical Progress

Failure to comply with regulations can delay or prevent the development of new therapies or interventions that could benefit patients.

In conclusion, understanding and adhering to the UK's legal framework for clinical testing, including regulations, guidelines, and ethical considerations, is essential to ensure the success, validity, and ethical integrity of medical research. Non-compliance can have serious legal, ethical, and scientific implications, underscoring the importance of conducting clinical trials in a compliant and ethical manner. This will be similar in other IT4Anxiety partner countries.

Examples of successful legal and ethical collaboration

Here are a few real-world case studies that illustrate successful legal and ethical collaboration in clinical testing:



Case Study 1

The Human Genome Project

The Human Genome Project (HGP) is a landmark example of a large-scale research collaboration that successfully navigated legal and ethical challenges. This international effort aimed to map and sequence the entire human genome. To ensure legal compliance and ethical integrity, the HGP established guidelines for data sharing, intellectual property rights, and informed consent. Researchers and institutions collaborated transparently, fostering a spirit of open science. The project's success led to the development of ethical frameworks for genomic research and data sharing, shaping subsequent research endeavours.



Case Study 2

Clinical Trials for Humanitarian Use

During public health emergencies, such as the Ebola outbreak in West Africa, collaboration between researchers, governments, and international organizations is crucial. Clinical trials for experimental treatments or vaccines require swift ethical review and regulatory approval to address urgent medical needs. In such cases, legal and ethical collaboration ensures that potential therapies are rigorously evaluated for safety and efficacy while respecting participant rights and informed consent. These collaborative efforts have led to the rapid development and deployment of life-saving interventions.



Case Study 3

Virtual Clinical Trials

Advancements in technology have enabled virtual clinical trials, where participants can engage remotely through digital platforms. This approach requires innovative legal and ethical collaboration to address issues related to data privacy, informed consent, and remote monitoring. Pharmaceutical companies, regulators, and technology providers work together to ensure that virtual trials adhere to regulatory standards and maintain ethical standards. Successful virtual trials, such as those conducted during the COVID-19 pandemic, demonstrate the potential of this collaborative approach in advancing clinical research while ensuring participant safety and rights.



Case Study 4

Collaborative Research Networks

Large-scale collaborative research networks, like the Cancer Moonshot initiative, bring together multiple institutions, researchers, and stakeholders to accelerate progress in cancer research. Legal and ethical collaboration is essential to navigate complex data sharing agreements, patient consent procedures, and intellectual property considerations. These networks prioritize transparent communication, standardized protocols, and harmonized ethical guidelines to ensure that research benefits patients and contributes to scientific knowledge.

These case studies highlight the diverse ways in which legal and ethical collaboration can contribute to the success of clinical testing initiatives. They emphasize the importance of transparent communication, regulatory compliance, and a shared commitment to upholding ethical principles in the pursuit of advancing medical knowledge and improving patient outcomes.

Document Summary

This document discusses the clinical and testing validation process, including the importance of study protocols, ethical considerations, and legal regulations (with examples for the UK). It emphasizes the significance of adhering to relevant laws and guidelines, as well as the potential legal risks of non-compliance. Also provided are real-world case studies illustrating successful legal and ethical collaboration in clinical testing. In addition the testing designs for six Startups tested as part of the IT4Anxiety Interreg project 2019-2023 are presented to demonstrate real 'field-tested' examples.



IT4ANXIETY
European Regional Development Fund

References

- [1] Hansson SO (2014) Why and for what are clinical trials the gold standard? *Scandinavian Journal of Public Health*, 42(Suppl 13), 41–48. Available at: <https://journals.sagepub.com/doi/10.1177/1403494813516712> [Accessed 20 August 2023].
- [2] Friedman LM, Furberg CD, DeMets DL, Reboussin DM and Granger CB (2015) *Fundamentals of Clinical Trials*. Heidelberg: Springer.
- [3] National Institute for Health and Care Research (2019) *Clinical Trials Guide*. NIHCR. Available at: <https://www.nihr.ac.uk/documents/clinical-trialsguide/20595#introduction> [Accessed 20 August 2023].
- [4] US Food and Drug Administration (2018) *Step 3: Clinical Research*. Maryland. Food and Drug Administration. Available at: <https://www.fda.gov/patients/drug-development-process/step-3-clinical-research> [Accessed 20 August 2023].
- [5] European Medicines Agency (2023) *Clinical Trials in Human Medicines*. Amsterdam. European Medicines Agency. Available at: <https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines> [Accessed 20 August 2023].
- [6] Deakin University (2023) *Quantitative Study Designs*. Melbourne. Deakin University. Available at: <https://deakin.libguides.com/quantitative-study-designs> [Accessed 20 August 2023].
- [7] Harvard University (2019) *Introduction to Human Subjects Research Protection*. Massachusetts. Harvard University. Available at: https://cuhs.harvard.edu/files/cuhs/files/urtp_curriculum-student_guide_february_2019.pdf [Accessed 20 August 2023].
- [8] Gupta UC (2013) Informed consent in clinical research: revisiting few concepts and areas. *Perspectives in Clinical Research*, 4(1), 26-32.
- [9] Kaiser K (2009) Protecting respondent confidentiality in qualitative research. *Qualitative Health Research*, 19(11), 1632-1641.
- [10] Owonikoko TK (2013) Upholding the principles of autonomy, beneficence, and justice in phase I clinical trials. *Oncologist*, 18(3), 242-244. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607517/> [Accessed 20 August 2023].
- [11] Østengaard L, Lundh A, Tjørnhøj-Thomsen T, Abdi S, Gelle MHA, Stewart LA, Boutron I and Hróbjartsson A (2020) Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study. *British Medical Journal*, 371:m3764 Available at: <http://dx.doi.org/10.1136/bmj.m3764> [Accessed 20 August 2023].
- [12] Council for International Organizations of Medical Sciences (2016) *International Ethical Guidelines for Health-related Research Involving Humans*. 4th ed. Geneva. Council for International Organizations of Medical Sciences (CIOMS).

- [13] Al-Jundi A and Sakka S (2016) Protocol writing in clinical research. *Journal of Clinical and Diagnostic Research*, 10(11), ZE10-ZE11. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198475/> [Accessed 20 August 2023].
- [14] De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJPM, Schroeder TV and Sox HC (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *The New England Journal of Medicine*, 351, 1250-1251.
- [15] World Health Organization (2023) *International Clinical Trials Registry Platform (ICTRP)*. Geneva, World Health Organization. Available at: <https://www.who.int/clinical-trials-registry-platform> [Accessed 20 August 2023].
- [16] National Library of Medicine (2023) *ClinicalTrials.gov*. Maryland, National Library of Medicine. Available at: <https://clinicaltrials.gov/> [Accessed 20 August 2023].
- [17] Abaid LN, Grimes DA and Schulz KF (2007) Reducing publication bias through trial registration. *Obstetrics & Gynecology*, 109(6), 1434-1437.
- [18] National Institutes of Health (2017) *Requirements for Registering & Reporting NIH-funded Clinical Trials in ClinicalTrials.gov*. Maryland, National Institutes of Health. Available at: <https://grants.nih.gov/policy/clinical-trials/reporting/index.htm> [Accessed 20 August 2023].
- [19] US Food and Drug Administration (2023) *FDA's Role: ClinicalTrials.gov Information*. Maryland, US Food and Drug Administration. Available at: <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/fdas-role-clinicaltrials-gov-information> [Accessed 20 August 2023].

Clinical Testing Framework:

Guide to collaborate
legally and ethically



Interreg 
EUROPEAN UNION
North-West Europe
IT4ANXIETY
European Regional Development Fund